Hypertension and its management in countries in Africa and the Middle East, with special reference to the place of β-blockade

References

• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12
   PubMed Web of Science ®Google Scholar
• World Health organization. Data and statistics. Available at: http://www.who.int/research/en/ [Last accessed January 2011]
   Google Scholar
• Ashour Z, Ibrahim MM, Appel LJ, et al. The Egyptian National Hypertension Project (NHP). Design and rationale. The NHP Investigative Team. Hypertension 1995;26:880-5
   PubMed Web of Science ®Google Scholar
• Al-Nozha MM, Abdullah M, Arafah MR, et al. Hypertension in Saudi Arabia. Saudi Med J 2007;28:77-84
   PubMed Web of Science ®Google Scholar
• Steyn K, Gaziano TA, Bradshaw D, et al. Hypertension in South African adults: results from the Demographic and Health Survey, 1998. J Hypertens 2001;19:1717-25
   PubMed Web of Science ®Google Scholar
• Tohme RA, Jurjus AR, Estephan A. The prevalence of hypertension and its association with other cardiovascular disease risk factors in a representative sample of the Lebanese population. J Hum Hypertens 2005;19:861-8
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Meysamie A, Khalilzadeh O, et al. Third National Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health 2009;9:167
   PubMed Web of Science ®Google Scholar
• Central Intelligence Agency. The World Factbook. Field listing: median age. Available at: https://www.cia.gov/library/publications/the-world-factbook/index.html [Last accessed January 2011]
   Google Scholar
• Ibrahim MM. Epidemiology of hypertension in Egypt. Saudi J Kidney Dis Transpl 1999;10:352-6
   PubMedGoogle Scholar
• Ibrahim MM, Rizk H, Appel LJ, et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). NHP Investigative Team. Hypertension 1995;26:886-90
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Appel LJ, Rizk HH, et al. Cardiovascular risk factors in normotensive and hypertensive Egyptians. J Hypertens 2001;19:1933-40
   PubMed Web of Science ®Google Scholar
• Akbar DH. Low rates of diabetic patients reaching good control targets. East Mediterr Health J 2001;7:671-8
   PubMedGoogle Scholar
• El-Hazmi MA, Al-Swailem AR, Warsy AS, et al. Lipids and related parameters in Saudi type II diabetes mellitus patients. Ann Saudi Med 1999;19:304-7
   PubMed Web of Science ®Google Scholar
• Mitwali AH, Al-Maatouq MA, Al-Wakeel J, et al. Hypercholesterolemia in healthy adult males – a public survey in central Saudi Arabia. Ann Saudi Med 1994;14:499-502
   PubMed Web of Science ®Google Scholar
• Al-Nozha MM, Arafah MR, Al-Maatouq MA, et al. Hyperlipidemia in Saudi Arabia. Saudi Med J 2008;29:282-7
   PubMed Web of Science ®Google Scholar
• Habib SH. Frequency distribution of atherogenic dyslipidemia in Saudi type 2 diabetic patients. Pak J Physiol 2006;2:20-3
   Google Scholar
• al-Shammari SA, Ali M, Al-Shammari A, et al. Blood lipid concentrations and other cardiovascular risk factors among Saudis. Fam Pract 1994;11:153-8
   PubMed Web of Science ®Google Scholar
• Akbar DH, Ahmed MM, Algamdi AA. Cardiovascular risk factors in Saudi Arabian and non-Saudi Arabian diabetic patients in Saudi Arabia. E Mediterr Health J 2003;9:884-92
   PubMedGoogle Scholar
• Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, et al. Obesity in Saudi Arabia. Saudi Med J 2005;26:824-9
   PubMed Web of Science ®Google Scholar
• Al-Nozha M, Al-Khadra A, Arafah MR, et al. Metabolic syndrome in Saudi Arabia. Saudi Med J 2005;26:1918-25
   PubMed Web of Science ®Google Scholar
• Stewart S, Wilkinson D, Becker A, et al. Mapping the emergence of heart disease in a black, urban population in Africa: the Heart of Soweto Study. Int J Cardiol 2006;108:101-8
   PubMed Web of Science ®Google Scholar
• Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008;371:915-22
   PubMed Web of Science ®Google Scholar
• Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation 2008;118:2360-7
   PubMed Web of Science ®Google Scholar
• Connor MD, Modi G, Warlow CP. Differences in the nature of stroke in a multiethnic urban South African population: the Johannesburg hospital stroke register. Stroke 2009;40:355-62
   PubMed Web of Science ®Google Scholar
• Albert MA. Heart failure in the urban African enclave of Soweto: a case study of contemporary epidemiological transition in the developing world. Circulation 2008;118:2323-5
   PubMed Web of Science ®Google Scholar
• Bärnighausen T, Welz T, Hosegood V, et al. Hiding in the shadows of the HIV epidemic: obesity and hypertension in a rural population with very high HIV prevalence in South Africa. J Hum Hypertens 2008;22:236-9
   PubMed Web of Science ®Google Scholar
• Tibazarwa K, Ntyintyane L, Sliwa K, et al. A time bomb of cardiovascular risk factors in South Africa: results from the Heart of Soweto Study ‘Heart Awareness Days’. Int J Cardiol 2009;132:233-9
   PubMed Web of Science ®Google Scholar
• Sibai AM, Fletcher A, Hills M, et al. Non-communicable disease mortality rates using the verbal autopsy in a cohort of middle aged and older populations in Beirut during wartime, 1983–93. J Epidemiol Community Health 2001;55:271-6
   PubMed Web of Science ®Google Scholar
• Jaddou HY, Bateiha AM, Al-Khateeb MS, et al. Epidemiology and management of hypertension among Bedouins in Northern Jordan. Saudi Med J 2003;24:472-6
   PubMed Web of Science ®Google Scholar
• Jaddou HY, Batiehah AM, Ajlouni KM. Prevalence and associated factors of hypertension: results from a three community-based survey, Jordan. J Hum Hypertens 1996;10:815-21
   PubMed Web of Science ®Google Scholar
• Jaddou HY, Bateiha AM, Ajlouni KM. Prevalence, awareness and management of hypertension in a recently urbanised community, eastern Jordan. J Hum Hypertens 2000;14:497-501
   PubMed Web of Science ®Google Scholar
• Mubarak FM, Froelicher ES, Jaddou HY, et al. Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann Saudi Med 2008;28:346-51
   PubMed Web of Science ®Google Scholar
• Shakhatreh FM, Suleiman AA, Mohammed FI, et al. Hypertension among females in a highly disadvantaged community in Jordan. Health Care Women Int 2008;29:39-53
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Abbasi M, Alikhani S, et al. Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. Am J Hypertens 2008;21:620-6
   PubMed Web of Science ®Google Scholar
• El-Shahat YI, Bakir SZ, Farjou N, et al. Hypertension in UAE citizens – preliminary results of a prospective study. Saudi J Kidney Dis Transpl 1999;10:376-81
   PubMedGoogle Scholar
• El-Reshaid K, Al-Owaish R, Diab A. Hypertension in Kuwait: the past, present and future. Saudi J Kidney Dis Transpl 1999;10:357-64
   PubMedGoogle Scholar
• el Mugamer IT, Ali Zayat AS, Hossain MM, et al. Diabetes, obesity and hypertension in urban and rural people of Bedouin origin in the United Arab Emirates. J Trop Med Hyg 1995;98:407-15
   PubMed Web of Science ®Google Scholar
• Addo J, Smeeth L, Leon DA. Hypertension in sub-Saharan Africa: a systematic review. Hypertension 2007;50:1012-18
   PubMed Web of Science ®Google Scholar
• El-Menyar A, Zubaid M, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol 2009;104:1018-22
   PubMed Web of Science ®Google Scholar
• Ali WM, Zubaid M, El-Menyar A, et al. The prevalence and outcome of hypertension in patients with acute coronary syndrome: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE). Blood Press 2010 Sep 15 [Epub ahead of print]
   Google Scholar
• The Egyptian Hypertension Society Working Group on Cardiovascular Prevention Guidelines (Delta-C Project). Egyptian guidelines on prevention of atherosclerotic cardiovascular disease. Available at: http://www.ehs-egypt.net [Last accessed January 2011]
   Google Scholar
• Saudi Hypertension Management Group. Saudi Hypertension Management Guidelines 2007. Available at: http://www.saudi-hypertension.org/home.htm [Last accessed January 2011]
   Google Scholar
• Seedat YK, Croasdale MA, Milne FJ, et al. South African hypertension guideline 2006. S Afr Med J 2006;96:337-62
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
   PubMed Web of Science ®Google Scholar
• National Heart, Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm [Last accessed January 2011]
   Google Scholar
• North of England Hypertension Guideline Development Group. Essential hypertension: managing adult patients in primary care. Centre for Health Services Research, report no. 111. Newcastle: University of Newcastle, 2004. Available at: http://www.nice.org.uk/guidance/index.jsp?action=download&o=30118 [Last accessed January 2011]
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Hypertension: management in adults in primary care: pharmacological update. London: Royal College of Physicians, 2006. Available at: http://guidance.nice.org.uk/CG34/Guidance/pdf/English [Last accessed January 2011]
   Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Mancia G, Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension–European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens 2008;26:164-8
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72
   PubMed Web of Science ®Google Scholar
• IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:379-92
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174:1737-42
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on CVD Prevention in clinical practice. Available at: http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/cvd-prevention.aspx [Last accessed January 2011]
   Google Scholar
• Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
   PubMed Web of Science ®Google Scholar
• Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71
   PubMed Web of Science ®Google Scholar
• The XAMOTEROL in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6
   PubMed Web of Science ®Google Scholar
• The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Are we misunderstanding beta-blockers. Review. Int J Cardiol 2007;120:10-27
   PubMed Web of Science ®Google Scholar
• Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002;105:2429-34
   PubMed Web of Science ®Google Scholar
• Maack C, Böhm M, Vlaskin L, et al. Partial agonist activity of bucindolol is dependent on the activation state of the human b1-adrenergic receptor. Circulation 2003;108:348-53
   PubMed Web of Science ®Google Scholar
• Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360:1631-9
   PubMed Web of Science ®Google Scholar
• The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
   PubMed Web of Science ®Google Scholar
• UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-76
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10
   PubMed Web of Science ®Google Scholar
• Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008;26:1602-11
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-19
   PubMed Web of Science ®Google Scholar
• Jansson K, Dahlström U, Karlberg BE, et al. The circulating renin–angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. J Intern Med 1999;245:435-43
   PubMed Web of Science ®Google Scholar
• Ellison KE, Hafley GE, Hickey K, et al. Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation 2002;106:2694-9
   PubMed Web of Science ®Google Scholar
• Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007;61:1592-602
   PubMed Web of Science ®Google Scholar
• Kountz DS. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Postgrad Med 2009;121:14-24
   PubMed Web of Science ®Google Scholar
• Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7
   PubMed Web of Science ®Google Scholar
• Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003;24:1928-32
   PubMed Web of Science ®Google Scholar
• Che Q, Schreiber MJ Jr, Rafey MA. Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med 2009;76:533-42
   PubMed Web of Science ®Google Scholar
• Giles TD, Bakris GL, Weber MA. Beta-blocker therapy in hypertension: a need to pause and reflect. J Am Coll Cardiol 2008;51:516-17
   PubMed Web of Science ®Google Scholar
• Bloch MJ. British hypertension society recommends that beta-blockers are no longer indicated as initial treatment of hypertension: has the pendulum swung too far? J Clin Hypertens (Greenwich) 2007;9:99–102
   PubMedGoogle Scholar
• Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J Suppl 2009;11:A3-A8
   Web of Science ®Google Scholar
• Akala FA, El-Saharty S. Public-health challenges in the Middle East and North Africa. Lancet 2006;367:961-4
   PubMed Web of Science ®Google Scholar